These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23954378)

  • 1. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
    Céspedes N; Arévalo-Herrera M; Felger I; Reed S; Kajava AV; Corradin G; Herrera S
    Vaccine; 2013 Oct; 31(42):4923-30. PubMed ID: 23954378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct.
    Céspedes N; Jiménez E; Lopez-Perez M; Rubiano K; Felger I; Alonso P; Arévalo-Herrera M; Corradin G; Herrera S
    Vaccine; 2014 May; 32(26):3179-86. PubMed ID: 24731811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
    Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
    Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
    Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
    Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys.
    Castellanos A; Arévalo-Herrera M; Restrepo N; Gulloso L; Corradin G; Herrera S
    Mem Inst Oswaldo Cruz; 2007 Jun; 102(3):411-6. PubMed ID: 17568948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
    Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
    Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.
    Cheng Y; Ito D; Sattabongkot J; Lim CS; Kong DH; Ha KS; Wang B; Tsuboi T; Han ET
    Malar J; 2013 Sep; 12():323. PubMed ID: 24034268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein.
    Herrera S; Bonelo A; Perlaza BL; Valencia AZ; Cifuentes C; Hurtado S; Quintero G; López JA; Corradin G; Arévalo-Herrera M
    Int J Parasitol; 2004 Dec; 34(13-14):1535-46. PubMed ID: 15582530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.
    Arévalo-Herrera M; Vera O; Castellanos A; Céspedes N; Soto L; Corradin G; Herrera S
    Am J Trop Med Hyg; 2011 Feb; 84(2 Suppl):21-7. PubMed ID: 21292874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
    Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
    Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
    Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.